 |
|
|
| |
SOLAR (Switch Onto Long-Acting Regimen) 12-Month Results -
Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF
|
| |
| |
CROI 2023 Feb 20-23
Moti N. Ramgopal1, Antonella Castagna2, Charles Cazanave3, Vicens Diaz-Brito4, Robin Dretler5, Shinichi Oka6, Olayemi Osiyemi7, Kenneth Sutton8, Denise Sutherland-Phillips8, Alessandro Berni9, Christine Latham8, Feifan Zhang10, Ronald D’Amico8, Kimberly Smith8, Jean van Wyk11
1Midway Immunology and Research Center, Fort Pierce, FL, United States; 2Vita-Salute University San Raffaele Scientific Institute, Milan, Italy;
3Department of Infectious Diseases, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France;
4Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Spain;
5Infectious Disease Specialists of Atlanta, Decatur, GA, United States; 6AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; 7Triple O Research Institute PA, West Palm Beach, FL, United States; 8ViiV Healthcare, Durham, NC, United States;
9GSK, Brentford, United Kingdom; 10GSK, Collegeville, PA, United States; 11ViiV Healthcare, Brentford, United Kingdom
|
| |
|
|
|
|
|
